Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy

Piera Rizzolo, Veronica Zelli, Valentina Silvestri, Virginia Valentini, Ines Zanna, Simonetta Bianchi, Giovanna Masala, Alessandro Mauro Spinelli, Maria Grazia Tibiletti, Antonio Russo, Liliana Varesco, Giuseppe Giannini, Carlo Capalbo, Daniele Calistri, Laura Cortesi, Alessandra Viel, Bernardo Bonanni, Jacopo Azzollini, Siranoush Manoukian, Marco MontagnaPaolo Peterlongo, Paolo Radice, Domenico Palli, Laura Ottini

Research output: Contribution to journalArticle

Abstract

Breast cancer (BC) in men is rare and genetic predisposition is likely to play a relevant role in its etiology. Inherited mutations in BRCA1/2 account for about 13% of all cases and additional genes that may contribute to the missing heritability need to be investigated. In our study, a well-characterized series of 523 male BC (MBC) patients from the Italian multicenter study on MBC, enriched for non-BRCA1/2 MBC cases, was screened by a multigene custom panel of 50 cancer-associated genes. The main clinical-pathologic characteristics of MBC in pathogenic variant carriers and non-carriers were also compared. BRCA1/2 pathogenic variants were detected in twenty patients, thus, a total of 503 non-BRCA1/2 MBC patients were examined in our study. Twenty-seven of the non-BRCA1/2 MBC patients were carriers of germline pathogenic variants in other genes, including two APC p.Ile1307Lys variant carriers and one MUTYH biallelic variant carrier. PALB2 was the most frequently altered gene (1.2%) and PALB2 pathogenic variants were significantly associated with high risk of MBC. Non-BRCA1/2 pathogenic variant carriers were more likely to have personal (p = 0.0005) and family (p = 0.007) history of cancer. Results of our study support a central role of PALB2 in MBC susceptibility and show a low impact of CHEK2 on MBC predisposition in the Italian population. Overall, our data indicate that a multigene testing approach may benefit from appropriately selected patients with implications for clinical management and counseling of MBC patients and their family members.

Original languageEnglish
Pages (from-to)390-400
Number of pages11
JournalInternational Journal of Cancer
Volume145
Issue number2
DOIs
Publication statusPublished - Jul 15 2019

Fingerprint

Male Breast Neoplasms
Genetic Predisposition to Disease
Italy
Multicenter Studies
Genes
Neoplasm Genes
Counseling
Breast Neoplasms

Keywords

  • BRCA1/2
  • cancer susceptibility genes
  • germline mutations
  • male breast cancer
  • multigene panel testing

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Insight into genetic susceptibility to male breast cancer by multigene panel testing : Results from a multicenter study in Italy. / Rizzolo, Piera; Zelli, Veronica; Silvestri, Valentina; Valentini, Virginia; Zanna, Ines; Bianchi, Simonetta; Masala, Giovanna; Spinelli, Alessandro Mauro; Tibiletti, Maria Grazia; Russo, Antonio; Varesco, Liliana; Giannini, Giuseppe; Capalbo, Carlo; Calistri, Daniele; Cortesi, Laura; Viel, Alessandra; Bonanni, Bernardo; Azzollini, Jacopo; Manoukian, Siranoush; Montagna, Marco; Peterlongo, Paolo; Radice, Paolo; Palli, Domenico; Ottini, Laura.

In: International Journal of Cancer, Vol. 145, No. 2, 15.07.2019, p. 390-400.

Research output: Contribution to journalArticle

Rizzolo, P, Zelli, V, Silvestri, V, Valentini, V, Zanna, I, Bianchi, S, Masala, G, Spinelli, AM, Tibiletti, MG, Russo, A, Varesco, L, Giannini, G, Capalbo, C, Calistri, D, Cortesi, L, Viel, A, Bonanni, B, Azzollini, J, Manoukian, S, Montagna, M, Peterlongo, P, Radice, P, Palli, D & Ottini, L 2019, 'Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy', International Journal of Cancer, vol. 145, no. 2, pp. 390-400. https://doi.org/10.1002/ijc.32106
Rizzolo, Piera ; Zelli, Veronica ; Silvestri, Valentina ; Valentini, Virginia ; Zanna, Ines ; Bianchi, Simonetta ; Masala, Giovanna ; Spinelli, Alessandro Mauro ; Tibiletti, Maria Grazia ; Russo, Antonio ; Varesco, Liliana ; Giannini, Giuseppe ; Capalbo, Carlo ; Calistri, Daniele ; Cortesi, Laura ; Viel, Alessandra ; Bonanni, Bernardo ; Azzollini, Jacopo ; Manoukian, Siranoush ; Montagna, Marco ; Peterlongo, Paolo ; Radice, Paolo ; Palli, Domenico ; Ottini, Laura. / Insight into genetic susceptibility to male breast cancer by multigene panel testing : Results from a multicenter study in Italy. In: International Journal of Cancer. 2019 ; Vol. 145, No. 2. pp. 390-400.
@article{1c0c159f8cd74dc9bbd459ca0e2dfd69,
title = "Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy",
abstract = "Breast cancer (BC) in men is rare and genetic predisposition is likely to play a relevant role in its etiology. Inherited mutations in BRCA1/2 account for about 13{\%} of all cases and additional genes that may contribute to the missing heritability need to be investigated. In our study, a well-characterized series of 523 male BC (MBC) patients from the Italian multicenter study on MBC, enriched for non-BRCA1/2 MBC cases, was screened by a multigene custom panel of 50 cancer-associated genes. The main clinical-pathologic characteristics of MBC in pathogenic variant carriers and non-carriers were also compared. BRCA1/2 pathogenic variants were detected in twenty patients, thus, a total of 503 non-BRCA1/2 MBC patients were examined in our study. Twenty-seven of the non-BRCA1/2 MBC patients were carriers of germline pathogenic variants in other genes, including two APC p.Ile1307Lys variant carriers and one MUTYH biallelic variant carrier. PALB2 was the most frequently altered gene (1.2{\%}) and PALB2 pathogenic variants were significantly associated with high risk of MBC. Non-BRCA1/2 pathogenic variant carriers were more likely to have personal (p = 0.0005) and family (p = 0.007) history of cancer. Results of our study support a central role of PALB2 in MBC susceptibility and show a low impact of CHEK2 on MBC predisposition in the Italian population. Overall, our data indicate that a multigene testing approach may benefit from appropriately selected patients with implications for clinical management and counseling of MBC patients and their family members.",
keywords = "BRCA1/2, cancer susceptibility genes, germline mutations, male breast cancer, multigene panel testing",
author = "Piera Rizzolo and Veronica Zelli and Valentina Silvestri and Virginia Valentini and Ines Zanna and Simonetta Bianchi and Giovanna Masala and Spinelli, {Alessandro Mauro} and Tibiletti, {Maria Grazia} and Antonio Russo and Liliana Varesco and Giuseppe Giannini and Carlo Capalbo and Daniele Calistri and Laura Cortesi and Alessandra Viel and Bernardo Bonanni and Jacopo Azzollini and Siranoush Manoukian and Marco Montagna and Paolo Peterlongo and Paolo Radice and Domenico Palli and Laura Ottini",
year = "2019",
month = "7",
day = "15",
doi = "10.1002/ijc.32106",
language = "English",
volume = "145",
pages = "390--400",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Insight into genetic susceptibility to male breast cancer by multigene panel testing

T2 - Results from a multicenter study in Italy

AU - Rizzolo, Piera

AU - Zelli, Veronica

AU - Silvestri, Valentina

AU - Valentini, Virginia

AU - Zanna, Ines

AU - Bianchi, Simonetta

AU - Masala, Giovanna

AU - Spinelli, Alessandro Mauro

AU - Tibiletti, Maria Grazia

AU - Russo, Antonio

AU - Varesco, Liliana

AU - Giannini, Giuseppe

AU - Capalbo, Carlo

AU - Calistri, Daniele

AU - Cortesi, Laura

AU - Viel, Alessandra

AU - Bonanni, Bernardo

AU - Azzollini, Jacopo

AU - Manoukian, Siranoush

AU - Montagna, Marco

AU - Peterlongo, Paolo

AU - Radice, Paolo

AU - Palli, Domenico

AU - Ottini, Laura

PY - 2019/7/15

Y1 - 2019/7/15

N2 - Breast cancer (BC) in men is rare and genetic predisposition is likely to play a relevant role in its etiology. Inherited mutations in BRCA1/2 account for about 13% of all cases and additional genes that may contribute to the missing heritability need to be investigated. In our study, a well-characterized series of 523 male BC (MBC) patients from the Italian multicenter study on MBC, enriched for non-BRCA1/2 MBC cases, was screened by a multigene custom panel of 50 cancer-associated genes. The main clinical-pathologic characteristics of MBC in pathogenic variant carriers and non-carriers were also compared. BRCA1/2 pathogenic variants were detected in twenty patients, thus, a total of 503 non-BRCA1/2 MBC patients were examined in our study. Twenty-seven of the non-BRCA1/2 MBC patients were carriers of germline pathogenic variants in other genes, including two APC p.Ile1307Lys variant carriers and one MUTYH biallelic variant carrier. PALB2 was the most frequently altered gene (1.2%) and PALB2 pathogenic variants were significantly associated with high risk of MBC. Non-BRCA1/2 pathogenic variant carriers were more likely to have personal (p = 0.0005) and family (p = 0.007) history of cancer. Results of our study support a central role of PALB2 in MBC susceptibility and show a low impact of CHEK2 on MBC predisposition in the Italian population. Overall, our data indicate that a multigene testing approach may benefit from appropriately selected patients with implications for clinical management and counseling of MBC patients and their family members.

AB - Breast cancer (BC) in men is rare and genetic predisposition is likely to play a relevant role in its etiology. Inherited mutations in BRCA1/2 account for about 13% of all cases and additional genes that may contribute to the missing heritability need to be investigated. In our study, a well-characterized series of 523 male BC (MBC) patients from the Italian multicenter study on MBC, enriched for non-BRCA1/2 MBC cases, was screened by a multigene custom panel of 50 cancer-associated genes. The main clinical-pathologic characteristics of MBC in pathogenic variant carriers and non-carriers were also compared. BRCA1/2 pathogenic variants were detected in twenty patients, thus, a total of 503 non-BRCA1/2 MBC patients were examined in our study. Twenty-seven of the non-BRCA1/2 MBC patients were carriers of germline pathogenic variants in other genes, including two APC p.Ile1307Lys variant carriers and one MUTYH biallelic variant carrier. PALB2 was the most frequently altered gene (1.2%) and PALB2 pathogenic variants were significantly associated with high risk of MBC. Non-BRCA1/2 pathogenic variant carriers were more likely to have personal (p = 0.0005) and family (p = 0.007) history of cancer. Results of our study support a central role of PALB2 in MBC susceptibility and show a low impact of CHEK2 on MBC predisposition in the Italian population. Overall, our data indicate that a multigene testing approach may benefit from appropriately selected patients with implications for clinical management and counseling of MBC patients and their family members.

KW - BRCA1/2

KW - cancer susceptibility genes

KW - germline mutations

KW - male breast cancer

KW - multigene panel testing

UR - http://www.scopus.com/inward/record.url?scp=85060589249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060589249&partnerID=8YFLogxK

U2 - 10.1002/ijc.32106

DO - 10.1002/ijc.32106

M3 - Article

C2 - 30613976

AN - SCOPUS:85060589249

VL - 145

SP - 390

EP - 400

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -